Altered epigenetic events in docetaxel-resistant human breast cancer cells

Lena Kastl, Iain Brown, Elizabeth Lamers, Andrew Craig Schofield

Research output: Contribution to journalArticle

Abstract

Docetaxel is an effective chemotherapy drug for breast cancer treatment. The mechanisms of resistance to docetaxel are poorly understood, however, epigenetic modifications, DNA methylation and histone modification, may be important. DNA methyltransferase (DNMT) 1, 3a and 3b are involved in DNA methylation whereas histone deacetylases control histone deacetylation. Epigenetic changes can be reversed using DNA methylation and histone deacetylation inhibitors. We hypothesise that inhibiting epigenetic events can reverse docetaxel resistance.
Methods: Docetaxel-sensitive and docetaxel-resistant MCF-7 breast cancer cells were treated with and without decitabine (DNA methylation inhibitor) or trichostatin A (histone deacetylation inhibitor). RT-PCR was performed to study DNMT gene expression and enzyme activity was also measured. Cell viability was measured by MTT assay.
Results: In docetaxel-resistant cells, DNMT3a and DNMT3b gene expression was decreased (8-fold; 13-fold) and so too was enzyme activity (20%). Decitabine treatment increased DNMT3a and DNMT3b gene expression (3-fold and 2-fold, respectively) as well as enzyme activity (30%) in docetaxel-resistant cells. In contrast, docetaxel-sensitive cells showed decreased DNMT3a and DNMT3b gene expression after decitabine treatment (both 3-fold). Response to docetaxel in resistant cells was not altered upon decitabine treatment. Addition of trichostatin A, however, led to an increased response to docetaxel (IC50: 42.5 µM vs. 22 µM; p = 0.14).
Conclusions: Histone deacetylation, leading to epigenetic silencing, may be a mechanism of docetaxel resistance in breast cancer cells. DNA methylation, however, does not appear to be involved in resistance.
Original languageEnglish
Pages (from-to)1193-1194
Number of pages2
JournalEuropean Journal of Surgical Oncology
Volume34
Issue number10
Early online date7 Sep 2008
DOIs
Publication statusPublished - Oct 2008

Fingerprint

docetaxel
Epigenomics
decitabine
Breast Neoplasms
DNA Methylation
Histones
trichostatin A
Gene Expression
Enzymes
Histone Code
Histone Deacetylases

Cite this

Altered epigenetic events in docetaxel-resistant human breast cancer cells. / Kastl, Lena; Brown, Iain; Lamers, Elizabeth; Schofield, Andrew Craig.

In: European Journal of Surgical Oncology, Vol. 34, No. 10, 10.2008, p. 1193-1194.

Research output: Contribution to journalArticle

Kastl, Lena ; Brown, Iain ; Lamers, Elizabeth ; Schofield, Andrew Craig. / Altered epigenetic events in docetaxel-resistant human breast cancer cells. In: European Journal of Surgical Oncology. 2008 ; Vol. 34, No. 10. pp. 1193-1194.
@article{b018ed06c875497c833f5c18e6448cd7,
title = "Altered epigenetic events in docetaxel-resistant human breast cancer cells",
abstract = "Docetaxel is an effective chemotherapy drug for breast cancer treatment. The mechanisms of resistance to docetaxel are poorly understood, however, epigenetic modifications, DNA methylation and histone modification, may be important. DNA methyltransferase (DNMT) 1, 3a and 3b are involved in DNA methylation whereas histone deacetylases control histone deacetylation. Epigenetic changes can be reversed using DNA methylation and histone deacetylation inhibitors. We hypothesise that inhibiting epigenetic events can reverse docetaxel resistance. Methods: Docetaxel-sensitive and docetaxel-resistant MCF-7 breast cancer cells were treated with and without decitabine (DNA methylation inhibitor) or trichostatin A (histone deacetylation inhibitor). RT-PCR was performed to study DNMT gene expression and enzyme activity was also measured. Cell viability was measured by MTT assay. Results: In docetaxel-resistant cells, DNMT3a and DNMT3b gene expression was decreased (8-fold; 13-fold) and so too was enzyme activity (20{\%}). Decitabine treatment increased DNMT3a and DNMT3b gene expression (3-fold and 2-fold, respectively) as well as enzyme activity (30{\%}) in docetaxel-resistant cells. In contrast, docetaxel-sensitive cells showed decreased DNMT3a and DNMT3b gene expression after decitabine treatment (both 3-fold). Response to docetaxel in resistant cells was not altered upon decitabine treatment. Addition of trichostatin A, however, led to an increased response to docetaxel (IC50: 42.5 µM vs. 22 µM; p = 0.14). Conclusions: Histone deacetylation, leading to epigenetic silencing, may be a mechanism of docetaxel resistance in breast cancer cells. DNA methylation, however, does not appear to be involved in resistance.",
author = "Lena Kastl and Iain Brown and Elizabeth Lamers and Schofield, {Andrew Craig}",
year = "2008",
month = "10",
doi = "10.1016/j.ejso.2008.06.169",
language = "English",
volume = "34",
pages = "1193--1194",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Altered epigenetic events in docetaxel-resistant human breast cancer cells

AU - Kastl, Lena

AU - Brown, Iain

AU - Lamers, Elizabeth

AU - Schofield, Andrew Craig

PY - 2008/10

Y1 - 2008/10

N2 - Docetaxel is an effective chemotherapy drug for breast cancer treatment. The mechanisms of resistance to docetaxel are poorly understood, however, epigenetic modifications, DNA methylation and histone modification, may be important. DNA methyltransferase (DNMT) 1, 3a and 3b are involved in DNA methylation whereas histone deacetylases control histone deacetylation. Epigenetic changes can be reversed using DNA methylation and histone deacetylation inhibitors. We hypothesise that inhibiting epigenetic events can reverse docetaxel resistance. Methods: Docetaxel-sensitive and docetaxel-resistant MCF-7 breast cancer cells were treated with and without decitabine (DNA methylation inhibitor) or trichostatin A (histone deacetylation inhibitor). RT-PCR was performed to study DNMT gene expression and enzyme activity was also measured. Cell viability was measured by MTT assay. Results: In docetaxel-resistant cells, DNMT3a and DNMT3b gene expression was decreased (8-fold; 13-fold) and so too was enzyme activity (20%). Decitabine treatment increased DNMT3a and DNMT3b gene expression (3-fold and 2-fold, respectively) as well as enzyme activity (30%) in docetaxel-resistant cells. In contrast, docetaxel-sensitive cells showed decreased DNMT3a and DNMT3b gene expression after decitabine treatment (both 3-fold). Response to docetaxel in resistant cells was not altered upon decitabine treatment. Addition of trichostatin A, however, led to an increased response to docetaxel (IC50: 42.5 µM vs. 22 µM; p = 0.14). Conclusions: Histone deacetylation, leading to epigenetic silencing, may be a mechanism of docetaxel resistance in breast cancer cells. DNA methylation, however, does not appear to be involved in resistance.

AB - Docetaxel is an effective chemotherapy drug for breast cancer treatment. The mechanisms of resistance to docetaxel are poorly understood, however, epigenetic modifications, DNA methylation and histone modification, may be important. DNA methyltransferase (DNMT) 1, 3a and 3b are involved in DNA methylation whereas histone deacetylases control histone deacetylation. Epigenetic changes can be reversed using DNA methylation and histone deacetylation inhibitors. We hypothesise that inhibiting epigenetic events can reverse docetaxel resistance. Methods: Docetaxel-sensitive and docetaxel-resistant MCF-7 breast cancer cells were treated with and without decitabine (DNA methylation inhibitor) or trichostatin A (histone deacetylation inhibitor). RT-PCR was performed to study DNMT gene expression and enzyme activity was also measured. Cell viability was measured by MTT assay. Results: In docetaxel-resistant cells, DNMT3a and DNMT3b gene expression was decreased (8-fold; 13-fold) and so too was enzyme activity (20%). Decitabine treatment increased DNMT3a and DNMT3b gene expression (3-fold and 2-fold, respectively) as well as enzyme activity (30%) in docetaxel-resistant cells. In contrast, docetaxel-sensitive cells showed decreased DNMT3a and DNMT3b gene expression after decitabine treatment (both 3-fold). Response to docetaxel in resistant cells was not altered upon decitabine treatment. Addition of trichostatin A, however, led to an increased response to docetaxel (IC50: 42.5 µM vs. 22 µM; p = 0.14). Conclusions: Histone deacetylation, leading to epigenetic silencing, may be a mechanism of docetaxel resistance in breast cancer cells. DNA methylation, however, does not appear to be involved in resistance.

U2 - 10.1016/j.ejso.2008.06.169

DO - 10.1016/j.ejso.2008.06.169

M3 - Article

VL - 34

SP - 1193

EP - 1194

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 10

ER -